LY2951742 Biomarker Study in Patients With Migraine

Trial Profile

LY2951742 Biomarker Study in Patients With Migraine

Phase of Trial: Phase 0

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Jan 2017 Status changed from recruiting to completed.
    • 10 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 09 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top